Absolute bioavailability and dose proportionality of BMS-181885, an antimigraine agent, following the administration of single intranasal doses to cynomolgus monkeys.
Srinivas
N R
NR
Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Route 206 and Provinceline Road, Princeton, New Jersey 08543-4000, USA.
Shyu
W C
WC
Soong
C W
CW
Greene
D
D
D000281:Administration, Intranasal; D000818:Animals; D019540:Area Under Curve; D001682:Biological Availability; D006207:Half-Life; D007211:Indoles / Q000493:pharmacokinetics*; D008252:Macaca fascicularis; D008297:Male; D009296:Nasal Cavity / Q000378:metabolism*; D010879:Piperazines / Q000493:pharmacokinetics*; D017366:Serotonin Receptor Agonists / Q000493:pharmacokinetics*; D014662:Vasoconstrictor Agents / Q000493:pharmacokinetics*
C111853:BMS 181885; D007211:Indoles; D010879:Piperazines; D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents